Follicle Stimulating Hormone Market to Reach $3.4 Billion, Globally, by 2033 at 5.9% CAGR: Allied Market Research

/EIN News/ -- Wilmington, Delaware, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Follicle Stimulating Hormone Market by Type (Recombinant FSH, and Urinary FSH), Application (Infertility Treatment, and Assisted Reproductive Technology) and End User (Hospitals, Fertility Clinics, and Cryobanks): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the follicle stimulating hormone market was valued at $1.9 Billion in 2023, and is estimated to reach $3.4 Billion by 2033, growing at a CAGR of 5.9% from 2024 to 2033. 

Request Sample of the Report on Follicle Stimulating Hormone Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A65456 

Prime determinants of growth 

The global follicle stimulating hormone market is experiencing growth due to surge in infertility rates, and surge in aging population. In addition, advancements in medical technology and pharmaceutical research have led to the development of novel formulations and delivery methods for follicle stimulating hormone medications, enhancing their efficacy, safety, and patient convenience. 

Report coverage & details 

Report Coverage	Details
Forecast Period	2024–2033
Base Year	2023
Market Size in 2023	$1.9 billion
Market Size in 2033	$3.4 billion
CAGR	5.90%
No. of Pages in Report	280
Segments Covered	Type, Application, End-User, and Region
Drivers	Surge in the infertility rates
	Surge in ageing population
	Unhealthy lifestyle
Opportunities	Advancements in medical technology
	Rise in awareness about fertility treatment
Restraint	High product cost

Want to Explore More, Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/A65456 

Segment Highlights 

The follicle stimulating hormone market is segmented into type, application, end-user, and region. On the basis of type, the market is divided into recombinant FSH, urinary FSH.  On The basis of application, the market is divided into infertility treatment, assisted reproductive technology. As per end-user, the market is segregated into hospitals, fertility clinics, cryobanks. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

By type, the recombinant FSH segment dominated the market share in 2023 attributed to the fact that recombinant FSH is produced using recombinant DNA technology in genetically engineered cell lines. This process ensures higher purity, consistency, and bioactivity of the hormone, minimizing the risk of impurities and contaminants commonly found in urinary-derived products. By application, the follicle stimulating hormone segment dominated the market share in 2023. This is attributed to rise in infertility rates, and surge in awareness and adoption of infertility treatment. 

For Purchase Related Queries/Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/A65456 

Regional Outlook 

North America dominated the market share in 2023, owing to advanced healthcare infrastructure, high awareness regarding infertility treatment, and the presence of leading market players. However, Asia-Pacific region is expected to register fastest growth during the forecasted period owing to increasing healthcare expenditure, growing awareness about infertility treatments, and rising prevalence of lifestyle-related health issues contributing to infertility. In addition, the improving healthcare infrastructure in emerging economies like China and India is expected to contribute significantly for the growth of the market in Asia-Pacific. 

Key Players 

• Pfizer Inc. 

• Novartis AG 

• Abbott Laboratories 

• Sanofi S.A. 

• Boehringer Ingelheim GmbH 

• Merck KGaA 

• Teva Pharmaceutical Industries Ltd. 

• Zydus Lifesciences Limited 

• Intas Pharmaceuticals Ltd. 

• Cipla Ltd 

The report provides a detailed analysis of these key players in the global follicle stimulating hormone market. These players have adopted different strategies such as new product approval to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. 

Get Customized Reports with your Requirements - https://www.alliedmarketresearch.com/request-for-customization/A65456 

Recent Developments in Follicle Stimulating Hormone Market Worldwide 

• In August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Myfembree. It is once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. 

Trending Reports in Healthcare Industry:  

Biomarkers Market - Global Opportunity Analysis and Industry Forecast, 2023-2032 

Synthetic Biology Market - Global Opportunity Analysis and Industry Forecast, 2023-2032 

Intravenous Immunoglobulin (IVIG) Market - Global Opportunity Analysis and Industry Forecast, 2023-2032 

Surgical Microscopes Market - Global Opportunity Analysis and Industry Forecast, 2023-2032 

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research: 

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. 

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access 

About Allied Market Research: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.  

Contact 

David Correa 

1209 Orange Street, 

Corporation Trust Center, 

Wilmington, New Castle, 

Delaware 19801 USA. 

Toll Free: +1-800-792-5285 

Int’l: +1-503-894-6022 

UK: +44-845-528-1300 

Hong Kong: +852-301-84916 

India (Pune): +91-20-66346060 

Fax: +1-855-550-5975 

help@alliedmarketresearch.com   

Web: https://www.alliedmarketresearch.com    

Follow Us on: LinkedIn Twitter